Ani Pharmaceuticals (ANIP) Payables (2010 - 2026)

Ani Pharmaceuticals has disclosed Payables across 17 years of filings, most recently posting $69.7 million for Q1 2026.

• Payables for Q1 2026 came in at $69.7 million, up 31.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.7 million (up 31.35% YoY), and the FY2025 annual result was $62.6 million, up 37.08% from the prior year.
• Payables came in at $69.7 million for Q1 2026 at Ani Pharmaceuticals, up from $62.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $69.8 million in Q3 2025 to a low of $19.0 million in Q3 2022.
• The 5-year median for Payables is $45.7 million (2024), against an average of $43.8 million.
• Across the five-year window, Payables jumped 113.0% in 2022 and advanced 3.13% in 2023, its largest moves.
• Ani Pharmaceuticals' Payables stood at $29.3 million in 2022, then climbed by 25.18% to $36.7 million in 2023, then gained by 24.46% to $45.7 million in 2024, then jumped by 37.08% to $62.6 million in 2025, then increased by 11.36% to $69.7 million in 2026.
• The last three Payables figures came in at $69.7 million (Q1 2026), $62.6 million (Q4 2025), and $69.8 million (Q3 2025), per Business Quant data.